BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 49.4% in April

BioCardia, Inc. (NASDAQ:BCDA) saw a significant drop in short interest in April. As of April 15th, there was short interest totalling 271,200 shares, a drop of 49.4% from the March 31st total of 535,900 shares. Based on an average daily trading volume, of 345,100 shares, the days-to-cover ratio is presently 0.8 days.

BioCardia Price Performance

Shares of NASDAQ:BCDA traded up $0.01 during midday trading on Friday, reaching $0.38. The company’s stock had a trading volume of 29,340 shares, compared to its average volume of 84,503. BioCardia has a fifty-two week low of $0.32 and a fifty-two week high of $2.92. The company has a market capitalization of $10.12 million, a P/E ratio of -0.68 and a beta of 1.47. The business’s fifty day simple moving average is $0.41 and its 200-day simple moving average is $0.50.

BioCardia (NASDAQ:BCDA) last announced its earnings results on Wednesday, March 27th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.20 million. BioCardia had a negative return on equity of 3,638.68% and a negative net margin of 2,425.79%. On average, analysts forecast that BioCardia will post -0.42 earnings per share for the current fiscal year.

Insider Activity

In other BioCardia news, CEO Peter Altman bought 108,108 shares of the stock in a transaction dated Tuesday, February 13th. The stock was bought at an average cost of $0.46 per share, for a total transaction of $49,729.68. Following the completion of the purchase, the chief executive officer now owns 555,447 shares in the company, valued at approximately $255,505.62. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last ninety days, insiders acquired 111,358 shares of company stock worth $50,942. 23.90% of the stock is owned by corporate insiders.

Institutional Trading of BioCardia

An institutional investor recently raised its position in BioCardia stock. CM Management LLC increased its position in BioCardia, Inc. (NASDAQ:BCDA) by 74.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 600,000 shares of the company’s stock after purchasing an additional 257,000 shares during the quarter. CM Management LLC owned approximately 2.78% of BioCardia worth $258,000 as of its most recent SEC filing. 20.57% of the stock is owned by hedge funds and other institutional investors.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.